Fax: (011) + 61-2-4968-4924
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?†
Version of Record online: 18 AUG 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 19, pages 4477–4487, 1 October 2009
How to Cite
Denham, J. W., Steigler, A., Wilcox, C., Lamb, D. S., Joseph, D., Atkinson, C., Tai, K.-H., Spry, N. A., Gleeson, P. S. and D'Este, C. (2009), Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?. Cancer, 115: 4477–4487. doi: 10.1002/cncr.24484
We are grateful for the significant clinical contributions to this trial of Drs. C. Jose and J. Matthews (Auckland); I. Franklin, G. Bryant, K. Gogna, G. Dickie, R. Allison, and L. Kenny (Brisbane); M. Jackson, G. Morgan, S. Cooper, A. Kneebone, and S. Turner (Sydney); P. Jeal, P. Fon, and M. Collins (Townsville); D. Byram and R. Lynch (Geelong); C. Johnson (Wellington); and C. Hamilton, P. O'Brien, and M. Back (Newcastle). We thank Ms. Dana Bill for her data evaluation, Ms. Kristen Palmer and Mrs. Jean Ball for their contributions to the centralized data management of the trial in Newcastle, and Ms. Rosemary Bradford for her skilful preparation of the article.
- Issue online: 17 SEP 2009
- Version of Record online: 18 AUG 2009
- Manuscript Accepted: 6 FEB 2009
- Manuscript Revised: 4 FEB 2009
- Manuscript Received: 26 NOV 2008
- Australian Government National Health and Medical Research Council. Grant Numbers: 9936572, 209801, 455520
- Hunter Medical Research Institute (Newcastle, Australia)
- AstraZeneca Pty Ltd (Sydney, Australia)
- Schering-Plough Pty Ltd (Sydney, Australia)
- AstraZeneca to attend a meeting
- 16American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 1035–1041.
- 21Regression models and life tables. J R Stat Soc. 1972; 34: 187–220..